Central pontine signal changes in Wilson's disease: distinct MRI morphology and sequential changes with de-coppering therapy

J Neuroimaging. 2007 Oct;17(4):286-91. doi: 10.1111/j.1552-6569.2007.00120.x.

Abstract

Background and purpose: Reports of central pontine myelinolysis (CPM)-like changes in Wilson's disease (WD) and its sequential changes are exceptional. The aim was to study the MRI characteristics of CPM-like changes in WD and the serial changes.

Methods: Among the 121 patients of WD, twenty (M:F:9:11, age at onset: 14.2 +/- 4.6 years) had features similar to CPM. All had progressive neuropsychiatric form of WD. All except five were on de-coppering treatment. None had acute deterioration or hepatic failure. Ten patients underwent repeat studies.

Results: Twenty patients with CPM-like changes manifested with characteristic phenotype of WD. Three distinct patterns of CPM-like changes were observed: (a) characteristic round shape -7, (b) "bisected" -9, and (c) "trisected" -4. Only one had signal changes suggesting extra-pontine myelinolysis. All patients had contiguous involvement of midbrain. Serial MRI evaluation in 10 patients, at mean interval period of 17.4 +/- 13.2 months, revealed complete reversal in one, partial improvement in five, and no change in three. Clinical and MRI improvement occurred pari passu, except in one.

Conclusions: CPM-like changes in WD are perhaps under-recognized and are distinct from the commonly known "osmotic demyelination." It is potentially reversible similar to other MRI features of WD.

MeSH terms

  • Adolescent
  • Adult
  • Astringents / therapeutic use
  • Chelating Agents / therapeutic use*
  • Chi-Square Distribution
  • Child
  • Disease Progression
  • Female
  • Health Status Indicators
  • Hepatolenticular Degeneration / drug therapy*
  • Hepatolenticular Degeneration / pathology*
  • Humans
  • India
  • Magnetic Resonance Imaging / methods*
  • Male
  • Penicillamine / therapeutic use
  • Phenotype
  • Pons / pathology*
  • Prognosis
  • Prospective Studies
  • Zinc Sulfate / therapeutic use

Substances

  • Astringents
  • Chelating Agents
  • Zinc Sulfate
  • Penicillamine